A European Medicines Agency (EMA) committee has recommended that a combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) plus two cycles of platinum-based chemotherapy be approved in the European Union (EU) as first-line treatment for advanced non-small cell lung cancer (NSCLC). The EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended the approval specifically for adults whose tumors contain no mutations in the EGFR or ALK genes. Opinions released by the CHMP are generally accepted by the European Commission (EC), which makes the final decisions on approving all…
You must be logged in to read/download the full post.
The post EU Approval Recommended for Opdivo-Yervoy-Chemo Combo for Advanced NSCLC appeared first on BioNewsFeeds.